- Home
- SST vs HIND Comparison
SST vs HIND Comparison
Compare SST & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SST | HIND |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | 300 | N/A |
| Industry | Diversified Commercial Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.9M | 28.0M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | SST | HIND |
|---|---|---|
| Price | $4.40 | $3.26 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 13.3K | N/A |
| Earning Date | 03-09-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $289,784,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.90 | N/A |
| 52 Week High | $15.00 | N/A |
Technical Indicators
Market Signals| Indicator | SST | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 45.78 | 44.57 |
| Support Level | $4.09 | $3.00 |
| Resistance Level | $4.60 | $3.25 |
| Average True Range (ATR) | 0.25 | 0.34 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 15.27 | 47.18 |
Price Performance
Historical ComparisonAbout SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.
About HIND Vyome Holdings Inc.
Vyome Holdings Inc is a reseach and development company. The Company operates in two segments, biotechnology and pharmaceutical products. The biotechnology segment comprises of operations around VT-1953, VT-1908, and VB-1953 programs that are in development, and the pharmaceutical segment comprises of antifungal products manufacturing and distribution.